Results 151 to 160 of about 2,212 (184)
Some of the next articles are maybe not open access.

New Indication for Rilonacept

AJN, American Journal of Nursing, 2021
Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age and older. The drug is given subcutaneously.
openaire   +1 more source

Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis

Annals of Pharmacotherapy, 2021
Objective To review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP). Data Sources A MEDLINE search was conducted between January 2006 and April 2021 using the ...
openaire   +2 more sources

Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Expert Opinion on Biological Therapy, 2009
Cryopyrin-associated periodic syndromes (CAPS) encompass a group of rare inherited, autoinflammatory disorders that represent a spectrum of one disease with varying degrees of severity. Until recently, there was no effective treatment for CAPS, but identification of the genetic basis of CAPS highlighted the pathogenic role of IL-1beta.Rilonacept is a ...
Hal M Hoffman
exaly   +3 more sources

What is rilonacept's role in treating recurrent pericarditis?

JAAPA, 2022
ABSTRACT The interleukin (IL)-1 antagonist rilonacept is approved by the FDA to treat recurrent pericarditis. In adults and adolescents with multiple recurrences of pericarditis, compared with placebo, rilonacept is associated with a lower risk of recurrent pericarditis, more persistent clinical response, normalized C-reactive protein within ...
openaire   +2 more sources

Rilonacept in the treatment of chronic inflammatory disorders

Drugs of Today, 2009
Rilonacept (IL-1 Trap/Arcalyst) is a long-acting interleukin-1 (IL-1) blocker developed by Regeneron Pharmaceuticals. Initially, Regeneron entered into a joint development effort with Novartis to develop rilonacept for the treatment of rheumatoid arthritis (RA) but this was discontinued following the review of phase II clinical data showing that IL-1 ...
openaire   +2 more sources

New drugs: Methylnaltrexone bromide, alvimopan, and rilonacept

Journal of the American Pharmacists Association, 2008
Agent for opioid-induced constipation Each year, an estimated 1.5 million Americans are treated with an opioid analgesic (e.g., morphine) on a continuous basis to relieve pain associated with incurable cancers, end-stage chronic obstructive pulmonary disease from emphysema, heart failure, and other advanced illnesses.
openaire   +2 more sources

Rilonacept--CAPS and beyond.

Annals of the New York Academy of Sciences, 2010
Rilonacept is a dimeric fusion protein consisting of the extracellular domains of interleukin (IL)-1 type 1 receptor and IL-1 receptor accessory protein joined to the constant region (Fc) of human immunoglobulin G1. By incorporating both components of the IL-1 binding complex, rilonacept is able to tightly bind IL-1 with picomolar affinity.
Neil, Stahl, Allen, Radin, Scott, Mellis
openaire   +1 more source

The IL-1 trap rilonacept resolves and prevents recurrent pericarditis

Nature Reviews Cardiology, 2020
In patients with recurrent pericarditis, treatment with rilonacept, an engineered fusion protein that acts as an IL-1 trap, leads to a rapid resolution of recurrent pericarditis episodes and reduces the risk of pericarditis recurrence.
openaire   +2 more sources

Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever

Annals of Internal Medicine, 2012
Currently, there is no proven alternative therapy for patients with familial Mediterranean fever (FMF) that is resistant to or intolerant of colchicine. Interleukin-1 is a key proinflammatory cytokine in FMF.To assess the efficacy and safety of rilonacept, an interleukin-1 decoy receptor, in treating patients with colchicine-resistant or -intolerant ...
Philip J, Hashkes   +13 more
openaire   +2 more sources

Rilonacept

Drugs of the Future, 2007
null Sorbera, L.A.   +2 more
openaire   +1 more source

Home - About - Disclaimer - Privacy